Recent advances in the care of the patient with malignant melanoma

Annals of Surgery

Volumn 225, Issue 1, 1997, Pages 1-16

  Reintgen, Douglas ^a   Balch, Charles M ^d   Kirkwood, John ^b,c   Ross, Merrick ^e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTIMONY TECHNETIUM SULFIDE TC 99M; BCG VACCINE; CORYNEBACTERIUM PARVUM EXTRACT; DACARBAZINE; GAMMA INTERFERON; INTERLEUKIN 2; NITROSOUREA; RECOMBINANT ALPHA2B INTERFERON; TECHNETIUM SULFUR COLLOID TC 99M; TRANSFER FACTOR;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; ELECTIVE SURGERY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MOLECULAR BIOLOGY; MYALGIA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; BIOPSY; CLINICAL TRIALS; HUMANS; INTERFERON ALFA-2B; INTRAOPERATIVE CARE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 0031013432     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199701000-00001     Document Type: Article

References (51)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996; 46:5-28.
2. Morton DL, Wen DR, Wong JH. el al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
3. Morton DL, Wen DR, Cochran AJ. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphodenectomy or "watch and wait." Surg Oncol Clin North Am 1992; 1:247-259.
4. Reintgen DS, Cruse CW, Berman C, et al. An orderly progression of melanoma nodal metastases, Ann Surg 1994; 220:759-767.
5. Ross MI, Reintgen DS, Balch CM. Selective lymphadenectomy: the emerging role of lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993; 9:219-223.
6. Heller R, Becker J, Wassalle J, et al. Detection of occult lymph node metastases in malignant melanoma. Ann Plast Surg 1992; 28:74-77.
7. Heller R, Becker J, Wassalle J, et al. Detection of submicroscopic lymph node metastases in patients with malignant melanoma. Arch Surg 1991; 126:1455-1460.
8. Wang X, Heller R, Van Voorhis N, et al. Detection of submicroscopic metastases with polymerase chain reaction in patients with malignant melanoma, Ann Surg 1994; 220:768-774.
9. Reintgen DS, Albertini J, Berman C, et al. Accurate nodal staging of malignant melanoma. Cancer Control J Moffitt Cancer Center 1995; 2:405-414.
10. Brossart P, Keilholz U, Willhauck M, et al. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993; 101:887-889.
11. Brossart P, Schmier J, Kruger S, et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995; 55:4065-4068.
12. Dale P, Wang Y, Conrad A, et al. Multiple marker polymerase chain reaction assay for evaluating circulating melanoma cells. Proc Am Soc Clin Oncol 1995; 14:413.
13. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297:627.
14. Sim FH, Taylor WF, Pritchard DJ, et al. Lyrnphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986; 61:697.
15. Balch CM, Milton GW, Cascinelli N, et al. Elective node dissection: pros and cons. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. 2nd ed, Philadelphia, PA: JB Lippincott; 1992:345.
16. Milton GW, Shaw HM, McCarthy WH, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients, Br J Surg 1982; 69:108.
17. Reintgen DS, Cox EB, McCarty KM Jr, et al. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198:379.
18. Breslow A. Thickness, cross-sectional areas and depth of melanoma in the prognosis of cutaneous melanoma. Ann Surg 1970; 72:902.
19. Balch CM, Soong S-j, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. 2nd ed. Philadelphia, PA: JB Lippincott; 1992:165.
20. Balch CM, Soong S-j, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localixed (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982; 196:677.
21. Schneebaum S, Briele HA, Walker MJ, et al. Cutaneous thick melanoma: prognosis and treatment. Arch Surg 1987; 122:707-711.
22. Soong S-j. A computerized mathematical model and scoring system for predicting outcome in patients with localizd melanoma. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. 2nd ed. Philadelphia, PA: JB Lippincott: 1992:200.
23. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980; 45:3012.
24. Reintgen DS, Paull DE, Seigler HF, et al. Sex-related survival differences in instances of melanoma. Surg Gynecol Obstet 1984; 159:367-362.
25. Austin P, Cruse CW, Lyman G, et al. The role of age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994; 1:487-494.
26. Slingluff C, Vollmer R, Reintgen D, Seigler HF. Lethal thin malignant melanoma. Ann Surg 1988; 208:150-161.
27. Norman J, Cruse CW, Espinos C, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg 1991; 162:432-437.
28. McCarthy WH, Uren RF, Thompson J, How lymphoscintigraphy aids melanoma treatment. Skin Cancer Found J 1996; 14:32-35.
29. Norman J, Wells K, Keamey R, et al. Identification of lymphatic drainage patterns in patients with cutaneous melanoma. Sem Surg Oncol 1993; 9:224-227.
30. Veronesi U, Adams J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49:2420.
31. Balch CM, Soong S-j, Bartolucci A, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age or younger. Ann Surg 1996; 224:255-266.
32. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results and controversies. J Clin Oncol 1988; 6:163, 392.
33. Thompson JF, McCarthy WH, Robinson E, et al. Sentinel lymph node biopsy in 102 patients with clinical stage 1 melanoma undergoing elective lymph node dissection. Presented at the 47th Cancer Symposium, Society of Surgical Oncology; March 23-26, 1995; Houston, TX (abstract).
34. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995; 130:654-658.
35. Veronesi U, et al. Distribution of axillary nodal metastases by level. Cancer 1987; 59:682-687.
36. Reintgen DS. Melanoma nodal metastases: biologic significance and therapeutic considerations. Surg Clin North Am 1996; 5:105-120.
37. Reintgen DS, Einstein A. The role of research in cost containment. Cancer Control J Moffitt Cancer Center 1995; 2:429-431.
38. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radiolymphoscintigraphy improves sentinel node identification in patients with melanoma. Ann Surg 1996; 223:217-224.
39. Militosis G, Albertini J, Berman C, et al. The tumor biology of melanoma nodal metastases. Am Surg 1996; 62:81-88.
40. Gershenwald J, Thompson W, Mansfield P, et al. Patterns of failure in melanoma patients after successful lymphatic mapping and negative sentinel node biopsy. Society of Surgical Oncology 1996, (abstract). Atlanta, GA, March 21-24, 1996.
41. Multicenter selective lymphadenectomy trial. National Cancer Institute Grant No. PO1 CA29605-12.
42. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684, J Clin Oncol 1996; 14:7-17.
43. Kirkwood J, et al. Toxicities and quality of life analysis of high dose adjuvant Interferon alfa for melanoma. J Clin Oncol (in press).
44. Balch C, Buzaid AC. Finally, a successful adjuvant therapy for high-risk melanoma. JCO 1996; 14:1-3.
45. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg 1990; 125:322-326.
46. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerace chain reaction. Lancet 1991; :1227-1229.
47. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant Interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13:2776.
48. Cascinelli N. Evaluation of efficacy of adjuvant rIFNa 2a in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol 1995; 14:410 (abstract).
49. Meyskens FL, Jr, Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus obersvation in high-risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl Cancer Inst 1995; 87:1710.
50. Kirkwood JM. Biologic therapy with interferon α and β: clinical applications - melanoma. In: Biologic Therapy of Cancer: Principles and Practice. Philadelphia, PA: JB Lippincott; 1995:388.
51. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985: 312:1604-1608.